Data Availability: Detailed quarterly EPS history and forward guidance not disclosed in current coverage. Trailing metrics shown below.
| Metric | Value | Status |
|---|---|---|
| Trailing EPS (TTM) | –$0.0602 | Negative |
| Revenue Growth YoY | +9.64% | Positive |
| EPS Growth YoY | Not Disclosed | Data Gap |
| Forward EPS | Not Disclosed | Data Gap |
| Earnings Date | Not Disclosed | Data Gap |
Assessment: ImmuCell is currently unprofitable on a per-share basis, with trailing EPS of –$0.06. However, revenue is growing at +9.64% YoY, suggesting operational traction despite losses. Without forward guidance or near-term earnings visibility, momentum assessment is constrained. The company exhibits early-stage biotech characteristics: growth in the numerator, profitability challenges in the denominator.
Data Availability: Detailed P&L, margin analysis, and cash flow metrics are not disclosed in current coverage.
| Metric | Value | Assessment |
|---|---|---|
| Gross Margin | Not Disclosed | Data Gap |
| Operating Margin | Not Disclosed | Data Gap |
| Net Margin | Negative (EPS –$0.06) | Unprofitable |
| ROE / ROIC | Not Disclosed | Data Gap |
| Free Cash Flow (TTM) | Not Disclosed | Data Gap |
Assessment: ImmuCell exhibits weak profitability metrics. The company is currently unprofitable on a GAAP basis. Revenue growth of 9.64% YoY provides some evidence of operational momentum, but without access to detailed margin structure, cash burn rates, or path to profitability, quality assessment is constrained. Early-stage biotechnology companies often operate at losses during clinical or commercial ramp phases; profitability timelines are typically multi-year.
Data Availability: Cash, debt, equity, and liquidity metrics are not disclosed in current coverage.
| Metric | Value | Status |
|---|---|---|
| Cash & Equivalents | Not Disclosed | Data Gap |
| Total Debt | Not Disclosed | Data Gap |
| Net Debt | Not Disclosed | Data Gap |
| Current Ratio | Not Disclosed | Data Gap |
| Net Debt / EBITDA | Not Disclosed | Data Gap |
Assessment: Balance sheet detail is not currently available. For a micro-cap biotech company ($100M market cap) with negative earnings, cash runway and liquidity are critical risk factors. The lack of disclosed financials elevates execution and funding risk. Investors should prioritize direct review of latest 10-Q/10-K filings to assess cash position, burn rate, and runway.
Context: Trailing P/E is undefined due to negative earnings. Forward metrics and sector comparables not disclosed.
| Metric | Value | Implication |
|---|---|---|
| Trailing P/E | Not Applicable (EPS negative) | N/A |
| Forward P/E | Not Disclosed | Data Gap |
| PEG Ratio | Not Calculable | Data Gap |
| Price / Sales | Not Disclosed | Data Gap |
| Price / FCF | Not Disclosed | Data Gap |
| EV / EBITDA | Not Disclosed | Data Gap |
Assessment: Traditional valuation multiples do not apply to unprofitable biotech firms. Valuation in this context is driven by clinical/commercial pipeline upside, market opportunity, and capital efficiency. At $100M market cap with 9.64% revenue growth and negative earnings, the stock is priced as a high-risk, early-stage development story. Without disclosed revenue, revenue multiples cannot be calculated. Beta of 0.55 suggests lower volatility relative to market, unusual for micro-cap biotech (typically higher beta). This warrants independent verification.
Data Availability: Analyst coverage, consensus ratings, and price targets not disclosed in current coverage.
| Metric | Value | Status |
|---|---|---|
| Consensus Rating | Not Disclosed | Data Gap |
| Mean Target Price | Not Disclosed | Data Gap |
| Target High | Not Disclosed | Data Gap |
| Target Low | Not Disclosed | Data Gap |
| Implied Upside / Downside | Not Calculable | Data Gap |
| Analyst Dispersion | Not Disclosed | Data Gap |
Assessment: Limited analyst coverage is typical for micro-cap biotechnology. Absence of disclosed consensus targets suggests either thin coverage or proprietary research only. Investors should source independent sell-side research or direct company communications for forward guidance and management outlook.
Data Availability: Institutional ownership, insider activity, and short interest not disclosed in current coverage.
| Risk Factor | Status | Assessment |
|---|---|---|
| Institutional Ownership | Not Disclosed | Data Gap |
| Insider Buying / Selling | Not Disclosed | Data Gap |
| Short Interest | Not Disclosed | Data Gap |
| Earnings Track Record | Unprofitable | Red Flag |
| Cash Burn Visibility | Not Disclosed | Red Flag |
| Regulatory / Clinical Risk | Not Disclosed | Data Gap |
Red Flags:
- Unprofitability: Company is cash-flow negative on a per-share basis, raising sustainability questions.
- Liquidity / Runway Risk: Without disclosed cash balances and burn rates, investors cannot independently model runway.
- Thin Coverage: Limited analyst following typical of micro-cap suggests lower institutional interest and less frequent re-review.
- No Target Prices: Absence of consensus targets indicates either lack of coverage or high disagreement.
- Micro-Cap Liquidity Risk: At $100M market cap, trading volume is likely thin, creating entry/exit challenges.
- Early-Stage Biotech Profile: ImmuCell is unprofitable (EPS –$0.06 TTM) but shows 9.64% revenue growth YoY, consistent with clinical/commercial ramp. Core business momentum exists; profitability path remains unclear.
- Critical Data Gaps: Lack of disclosed balance sheet, cash flow, detailed P&L, and forward guidance severely constrains fundamental analysis. Investors must source 10-Q/10-K directly for cash runway and burn-rate visibility.
- Valuation: Speculative Risk. Traditional multiples (P/E, P/S, EV/EBITDA) unavailable or immaterial. Stock is priced on pipeline optionality and market potential; downside in liquidation / financing risk is material.
- Micro-Cap Liquidity & Institutional Risk: $100M market cap, thin analyst coverage, no consensus targets, and likely limited trading volume create execution and exit barriers. Suitable only for long-term, high-conviction thesis investors.
- Recommended Next Steps: (1) Review latest 10-Q and SEC filings for cash position, runway, and cash burn. (2) Assess clinical/commercial pipeline milestones and timelines. (3) Evaluate management team track record. (4) Consider position sizing at ≤2–3% of portfolio given risk profile.
ICCC Stock Analysis & Forecast
Is ICCC a Good Investment in 2026?
Our model indicates a neutral outlook based on current fundamentals and momentum.
ICCC Stock Forecast
Based on recent earnings trends, valuation metrics, and sector performance, ICCC shows balanced risk-reward characteristics.
Should You Buy ICCC Now?
Investors should consider market conditions, volatility, and long-term positioning before taking a position in ICCC.